Success Metrics

Completion Rate
0%(0/1)
Active Trials
1(33%)
Terminated
1(33%)

Phase Distribution

Ph phase_1
2
67%
Ph not_applicable
1
33%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Terminated(1)

Detailed Status

Not yet recruiting1
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
0.0%
Most Advanced
Phase 1

Trials by Phase

Phase 12 (66.7%)
N/A1 (33.3%)

Trials by Status

not_yet_recruiting133%
terminated133%
recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
not_yet_recruitingnot_applicable

Bilirubin Thresholds in Preterm Infants on Neonatal Intensive CarE Units: The B-NICE Trial

NCT07674537
terminatedphase_1

Siplizumab for Sickle Cell Disease Transplant

NCT06078696
recruitingphase_1

131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)

NCT07015684

Clinical Trials (3)

Showing 3 of 3 trials
NCT07674537Not Applicable

Bilirubin Thresholds in Preterm Infants on Neonatal Intensive CarE Units: The B-NICE Trial

Not Yet Recruiting
NCT06078696Phase 1

Siplizumab for Sickle Cell Disease Transplant

Terminated
NCT07015684Phase 1

131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
3